Chinese pharma app seals $133m series D funding

Pharmaceutical trading platforms like Yaoshibang help stores in dispersed and remote cities to meet the increasing demand of patients.

Chinese B2B pharmaceutical trading platform Yaoshibang has completed its $133 million Series D fundraising on Monday.

Tiger Global, H Capital and DCM Ventures all participated.

Proceeds will be used to hire more talent and to improve platform security.

Yaoshibang is a B2B platform which connects pharmaceutical companies, drug stores and clinics. It sells medicines wholesale together with software services so that chemists can track purchases. Launched in 2015, the platform also offers a training programme for pharmacists.

The platform, which serves 200,000 chemists and clinics online, claims that it sells a gross volume of Rmb10 billion $1.4 billion...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222